Premium
The Effect of Bisphosphonate Use on Coenzyme Q10 Serum Levels
Author(s) -
Hirsh Steven,
Huber Luke,
Schmid Kira,
Woolger Judith,
Strum Stephen,
Joyal Steven,
CohnGelwasser Elisabeth
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.738.13
Subject(s) - bisphosphonate , coenzyme q10 , farnesyl pyrophosphate , pharmacology , chemistry , medicine , osteoporosis , endocrinology , enzyme , biochemistry , atp synthase
Background It has been proposed in the literature that the nitrogen‐containing bisphosphonates bind to and inhibit the activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway for cholesterol and coenzyme Q10 (CoQ10) synthesis. This suggests that bisphosphonate use may decrease serum levels of CoQ10. Objective: The aim of this case report analysis is to assess the effect of a bisphosphonate, alendronate sodium, on serum CoQ10 levels. Methods: 7 participants diagnosed with osteoporosis were administered a single tablet of alendronate sodium 70mg once per week for 8 weeks. Assessment of serum CoQ10 concentrations were conducted at baseline, day 14, day 30 and day 60. Results: Statistical analysis was conducted for the 6 completing participants. Compared to baseline, there was a non‐significant mean decrease of 0.1400 mcg/ml in the CoQ10 level at day 14, a non‐significant mean increase of 0.1250 mcg/ml at day 30, and a statistically significant mean increase of 0.1900 mcg/ml at day 60. Conclusion The results indicate that there was no decrease in the CoQ10 level as a result of bisphosphonate ingestion from day 1 to day 60. These results suggest inhibition of farnesyl pyrophosphate synthase by a nitrogen containing bisphosphonate (alendronate sodium) is limited in its inhibitory effect upon the pathway that leads to the synthesis of CoQ10.